Skip to main content
. 2022 Jan 13;22:63. doi: 10.1186/s12913-021-07390-4

Fig. 3.

Fig. 3

Potential cost-savings (million €, %) through the splitting of single-tablet regimens and replacing all substance partners with generic antiretroviral drugs between 1/2017 and 2/2019